NuCana PLC
NCNA0.039USD
-0.001-2.48%
종가 05/22, 16:00（ET）시세는 15분 지연됩니다
223.85K시가총액
손실P/E TTM
자세한 내용은 NuCana PLC 회사
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
회사 정보
회사 코드NCNA
회사 이름NuCana PLC
상장일Sep 28, 2017
설립일1997
CEOMr. Hugh S. Griffith
직원 수20
유형Depository Receipt
회계 연도 종료Sep 28
주소Lochside House
도시EDINBURGH
증권 거래소NASDAQ Capital Market Consolidated
국가United Kingdom
우편 번호EH12 9DT
전화4401313571111
웹사이트https://www.nucana.com/
회사 코드NCNA
상장일Sep 28, 2017
설립일1997
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
10.60K
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
1.33K
+18.87%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
749.00
+298.40%
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Christopher F. Brinzey
Mr. Christopher F. Brinzey
Investor Relations
Investor Relations
--
--
Dr. David Harrison, M.D.
Dr. David Harrison, M.D.
Head - Translational Studies
Head - Translational Studies
--
--
Mr. Donald (Don) Munoz
Mr. Donald (Don) Munoz
Chief Financial Officer
Chief Financial Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
10.60K
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
1.33K
+18.87%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
749.00
+298.40%
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주주
업데이트 시간: Sat, May 17
업데이트 시간: Sat, May 17
주주 통계
유형
주주 통계
주주
비율
Sofinnova Investments, Inc
2.34%
Abingworth Management Limited
1.56%
Schonfeld Strategic Advisors LLC
0.52%
Acadian Asset Management LLC
0.45%
XTX Markets LLC
0.24%
Other
94.89%
주주 통계
주주
비율
Sofinnova Investments, Inc
2.34%
Abingworth Management Limited
1.56%
Schonfeld Strategic Advisors LLC
0.52%
Acadian Asset Management LLC
0.45%
XTX Markets LLC
0.24%
Other
94.89%
유형
주주
비율
Venture Capital
4.14%
Investment Advisor/Hedge Fund
0.59%
Hedge Fund
0.52%
Investment Advisor
0.30%
Individual Investor
0.15%
Research Firm
0.07%
Other
94.23%
기관 주식 보유
업데이트 시간: Tue, Mar 4
업데이트 시간: Tue, Mar 4
보고 기간
기관 수
보유 주식
비율
변동
2025Q1
51
654.56K
8.46%
+343.44K
2024Q4
52
469.91K
11.91%
+42.72K
2024Q3
52
279.81K
7.09%
-247.00K
2024Q2
51
362.89K
15.79%
-1.48K
2024Q1
59
340.51K
14.80%
-343.96K
2023Q4
65
549.25K
25.71%
-320.80K
2023Q3
68
668.24K
31.65%
-112.66K
2023Q2
71
571.34K
27.26%
-362.30K
2023Q1
81
667.89K
31.87%
-504.63K
2022Q4
87
672.60K
32.11%
-559.71K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Sofinnova Investments, Inc
199.52K
3.51%
+199.52K
--
Feb 14, 2025
Abingworth Management Limited
133.33K
2.35%
--
--
Dec 31, 2024
Schonfeld Strategic Advisors LLC
45.07K
0.79%
+45.07K
--
Dec 31, 2024
Acadian Asset Management LLC
42.41K
0.75%
+18.79K
+79.54%
Dec 31, 2024
Glass Jacobson Wealth Advisors
15.00K
0.26%
--
--
Dec 31, 2024
Griffith (Hugh S)
10.60K
0.19%
--
--
Dec 31, 2023
LUNIS Vermögensmanagement AG
8.90K
0.16%
-1.00
-0.01%
Sep 30, 2024
더 보기
관련 ETF
이름
비율
데이터 없음
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
날짜
유형
비율
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
